The circulating concentration of IGF-II is generally unchanged even in non-islet cell tumor-induced hypoglycemia; a relatively rare clinical condition that is manifest by very clear metabolic effects arising from excess IGF-II is produced by aggressive tumors [4]. This evidence concerns the gene IGF2 and pancreatic neuroendocrine tumor.